The company also announces it “expects its current cash position to fund planned operations into 2027 and through multiple upcoming clinical readouts, including two additional readouts in MDD with ALTO-203 and ALTO-300 expected in the first half of 2025.” Shares are down 47% or $6.78 afterhours at $7.75.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
- Alto Neuroscience falls -3.8%
- Four new option listings and one option delisting on September 18th
- Alto Neuroscience: No demonstrative efficacy in MDD patients with vortioxetine
- Wedbush bullish on Alto Neuroscience, initiates with an Outperform